Durvalumab Consolidation Treatment Following Concurrent Chemoradiotherapy in Limited-Stage SCLC: ADRIATIC China Subgroup Analysis.

Ma L, Wang Q, Fang J, Shi A, Wu L, Lu S, Zhu Z, Liu Y, Wang Q, Jiang H, Li X, Wang M, Chen Y, Lu H, Duan Y, Meng R, Jiang L, Zhao L, Zhu W, Chen Y, Szadkowski L, Olivo Y, Senan S

Open source

DOI: 10.1016/j.jtocrr.2026.101022
Published: 2026 Aug
Container: JTO clinical and research reports
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtocrr.2026.101022,
  title = {Durvalumab Consolidation Treatment Following Concurrent Chemoradiotherapy in Limited-Stage SCLC: ADRIATIC China Subgroup Analysis.},
  author = {Ma L and Wang Q and Fang J and Shi A and Wu L and Lu S and Zhu Z and Liu Y and Wang Q and Jiang H and Li X and Wang M and Chen Y and Lu H and Duan Y and Meng R and Jiang L and Zhao L and Zhu W and Chen Y and Szadkowski L and Olivo Y and Senan S},
  year = {2026},
  journal = {JTO clinical and research reports},
  doi = {10.1016/j.jtocrr.2026.101022},
  url = {https://doi.org/10.1016/j.jtocrr.2026.101022}
}

RIS

TY  - JOUR
TI  - Durvalumab Consolidation Treatment Following Concurrent Chemoradiotherapy in Limited-Stage SCLC: ADRIATIC China Subgroup Analysis.
AU  - Ma L
AU  - Wang Q
AU  - Fang J
AU  - Shi A
AU  - Wu L
AU  - Lu S
AU  - Zhu Z
AU  - Liu Y
AU  - Wang Q
AU  - Jiang H
AU  - Li X
AU  - Wang M
AU  - Chen Y
AU  - Lu H
AU  - Duan Y
AU  - Meng R
AU  - Jiang L
AU  - Zhao L
AU  - Zhu W
AU  - Chen Y
AU  - Szadkowski L
AU  - Olivo Y
AU  - Senan S
PY  - 2026
JO  - JTO clinical and research reports
DO  - 10.1016/j.jtocrr.2026.101022
UR  - https://doi.org/10.1016/j.jtocrr.2026.101022
ER  -

APA

L, M., Q, W., J, F., A, S., L, W., S, L., Z, Z., Y, L., Q, W., H, J., X, L., M, W., Y, C., H, L., Y, D., R, M., L, J., L, Z., W, Z., Y, C., L, S., Y, O., & S, S. (2026). Durvalumab Consolidation Treatment Following Concurrent Chemoradiotherapy in Limited-Stage SCLC: ADRIATIC China Subgroup Analysis.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2026.101022

Source records

pubmed · retrieved 2026-09-25T10:11:36.787Z